Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Return on Sales (2022 - 2025)

Oramed Pharmaceuticals' Return on Sales history spans 4 years, with the latest figure at 63.46% for Q4 2025.

  • For Q4 2025, Return on Sales changed N/A year-over-year to 63.46%; the TTM value through Dec 2025 reached 63.46%, changed N/A, while the annual FY2025 figure was 32.01%, 961.0% up from the prior year.
  • Return on Sales reached 63.46% in Q4 2025 per ORMP's latest filing, up from 17.18% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 63.46% in Q4 2025 to a low of 35.26% in Q2 2024.
  • Average Return on Sales over 4 years is 2.93%, with a median of 5.15% recorded in 2024.
  • Peak YoY movement for Return on Sales: plummeted -3332bps in 2024, then surged 3249bps in 2025.
  • A 4-year view of Return on Sales shows it stood at 13.56% in 2022, then surged by 119bps to 2.61% in 2023, then crashed by -298bps to 5.15% in 2024, then surged by 1333bps to 63.46% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Return on Sales are 63.46% (Q4 2025), 17.18% (Q3 2025), and 2.77% (Q2 2025).